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Methods
• Patients were eligible with a diagnosis of advanced breast, colorectal, lung, ovarian or pancreatic cancer or with advanced 
cancer of any histology with evidence of deregulated RB cell cycle control
• Safety and tolerability, including cycle-1 dose-limiting toxicities (DLTs) were evaluated
• Dose-limiting toxicities were graded using the National Cancer Institute Common Toxicity Criteria for Adverse Events 
(NCI-CTCAE) version 5.0
• Serial plasma PK, and PD in PBMCs were obtained on days 1 and 15 in cycle 1
• POLR2A mRNA expression within treated patients’ PBMCs were measured relative to a set of control genes identified as 
unresponsive to SY-5609 in preclinical models; POLR2A mRNA fold-change within a patient was determined by normalizing 
to the pre-dose sample on day 1
• Tumor responses were assessed per RECIST version 1.1
• Data presented from August 21, 2020 snapshot
ENA Virtual Symposium  • October 24 – 25, 2020
Single agent 
• 3 mg identified as MTD in continuous daily 
dosing cohort
 –  2 DLTs each at 5 mg and 4 mg dose levels
  • 5 mg: Grade 3 nausea (1) and   
  thrombocytopenia (1)
  • 4 mg: Grade 3 fatigue (1) and 
  abdominal pain (1)
 • Alternate regimens ongoing 
 –  7 days on / 7 days off; 4 mg
 –  5 days on / 2 days off; 4 mg
• Lung cancer expansion ongoing at 3 mg 
continuous daily dosing 
Combination with fulvestrant 
• Enrollment at 3 mg daily was expanded and 
continues following safety clearance
• Dose escalation of the combination is ongoing
SY-5609 Safety Overview
Response Summary
Dose-dependent Increases Observed in SY-5609 Plasma Exposures and PBMC POLR2A 
PD Responses 
Results for each dose and timepoint represent mean +/- standard error
(a) Includes 2 patients treated in combination with fulvestrant, comparable PK and PD observed between patients treated with 3 mg  single agent SY-5609 versus in combination with fulvestrant
(b) Concentrations < BLQ (0.3 ng/mL) 
• Single agent SY-5609 Safety Summary
 –  The majority of reported AEs were low grade
 –  The most common AEs* were nausea, diarrhea, fatigue, platelet count decrease and vomiting 
 –  4/13 (31%) patients developed an SAE (all causality): nausea and ascites, fatigue, colitis, vomiting
• In the 4 patients treated with combination SY-5609 and fulvestrant, the safety profile was consistent with that seen for single 
agent treatment
• CDK7 controls two key processes which when deregulated, are important in the development of cancer: transcription and cell 
cycle control
• SY-5609 is an oral, noncovalent, highly selective and potent CDK7 inhibitor:
 –  Demonstrates robust anti-tumor activity at well-tolerated doses in patient-derived xenograft (PDX) models with enrichment for deep and   
 durable responses in models with oncogenic alterations in the RB pathway (SCLC, TNBC, HGSOC) and MAPK-pathway (CRC, PDAC, NSCLC)
 –  Demonstrates robust anti-tumor activity in combination with fulvestrant at well-tolerated doses in HR+BC PDX models resistant to CDK4/6  
 inhibitor treatment
• Preclinical in vivo studies identified a PD gene expression marker, POLR2A mRNA, associated with SY-5609 dose-dependent 
tumor growth inhibition (Johannessen, ASCO 2020, Poster #3585)
• Preclinical data support tumor growth inhibition in preclinical models when SY-5609 is dosed with a continuous or intermittent 
dosing regimen
• A phase 1 first in human dose escalation study (NCT04247126) was initiated to evaluate the optimal dose and regimen as a 
single agent in select solid tumors, and in combination with fulvestrant in hormone receptor positive breast cancer (HR+BCA)* 
• Here we report initial results with a focus on safety, tolerability, PK, and PD (POLR2A) in the 28-day single agent continuous 


























Single Agent Related Adverse Events (≥15%)
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Single Agent Adverse Events (≥15%); All Causality
SY-5609-101 Study Status Summary 
(a) Safety population was defined as patients who took at least one dose of study drug (SY-5609) (b) All enrolled 
patients who received at least 1 dose of study drug and have at least 1 post-baseline disease assessment 
(c) Per RECIST v1.1
59% (10/17) of patients enrolled had previously detected 
mutations indicative of deregulated RB cell cycle control
Dose (mg) 1 3 4 5 3 Total
Safety Populationa 1 4 3 5 4 17





Duration of Treatment:  
Median Days (range) 
Patient Withdrawn from Treatment 6 (46) 1 (25)
     Disease Progressionc 3 (23) 1 (25)
     Adverse Event 1 (8) 0 (0)
     Withdrew Consent 1 (8) 0 (0)








Number of Patients Enrolled, N (%)
Number of Patients Enrolled by Dose Level
N
40 (7-156) 34 (3-49)
A subject was counted only once within each preferred term
*Most common AE defined as those observed in ≥ 25% of the patients
Baseline Characteristics, N (%) N=17 (100)
Median Age, Years (range)  64 (48-76)
Gender, n (%)
 Female  14 (82)
 Male  3 (18)
≥ 5 Prior Lines of Therapy, n (%)  8 (47)
 Median Number of Prior Lines (range)  4 (1-12)
Tumor Type, n (%)
 Breast   
  CCND1 amplification, N=1
  RB1 deletion, N=1
 Colorectal  
  CCND2 amplification, N=2
 Ovarian  
  CCNE1 amplification, N=2
 Pancreatic  
  CDKN2A mutation, N=2
 Endometrial  
  CCNE1 amplification, N=1
 Esophageal  


























































* Papadopoulos, ASCO 2020, Poster #TPS3662
Conclusions
• SY-5609, a highly selective and potent oral inhibitor of CDK7, 
showed dose-dependent effects on POLR2A gene expression 
demonstrating proof of mechanism in patients with advanced 
solid tumors 
• POLR2A PD response at 3 mg QD reached levels associated 
with tumor regressions in preclinical models, and with CDK7 
target engagement at which clinical activity was observed with a 
first generation intravenous CDK7 inhibitor 
• As a single agent and in combination with fulvestrant, SY-5609 
exhibited approximately dose proportional PK, moderate-high 
interpatient variability, minimal accumulation with repeat dosing, 
and a steady state half-life compatible with once daily dosing 
• The emerging safety profile demonstrates that the most common 
AEs to date were nausea, diarrhea, fatigue, platelet count 
decrease and vomiting 
• MTD has been defined for the continuous daily dosing schedule 
at 3 mg  
• Expansion cohorts in breast and lung cancer patients have 
opened using the 3 mg dose to further assess PK, PD, and early 
clinical activity in more homogenous cancer patient populations
• Alternate clinical dosing regimens being explored are supported 
by preclinical models where tumor regressions were maintained 
with intermittent dosing
• SY-5609 exhibited approximately dose proportional PK with 
moderate-high interpatient variability and minimal 
accumulation on repeat dosing
• SY-5609 had a half-life at steady state (~15 hrs) compatible 
with once daily dosing 
• Co-administration with fulvestrant had no impact on PK of 
SY-5609
• POLR2A PD responses measured on Day 1 across all dose 
levels had dose-dependent increases over 24 hours
Increased SY-5609 Plasma Exposures and PBMC POLR2A PD Responses Achieved at Steady 
State with Once Daily Dosing
SY-5609 Dosed at 3 mg Daily Induces POLR2A Elevations Associated with Regressions in 
Preclinical Models and Target Levels of CDK7 Occupancy in Patients
• POLR2A PD responses in PBMCs of SY-5609-101 patients treated at 3 mg attain a ≥ 2.3-fold change from baseline that is consistent with:
 –  POLR2A responses in tumor tissue at daily doses that induce regressions (>100% TGI) in BRAF-mutant CRC patient-derived xenografts
 –  70% CDK7 occupancy in PBMCs from patients treated with the covalent CDK7 inhibitor SY-1365 (Study SY-1365-101)
  • ~70% trough CDK7 occupancy observed at SY-1365 dose associated with apoptosis and clinical activity (durable PR in a heavily pre-treated  
  ovarian clear cell cancer patient) (Juric, ENA 2018)
  • ~70% trough occupancy in tumor tissue associated with regressions in preclinical xenograft models treated with SY-1365
• POLR2A fold-change measured at trough (24h) after single dose
• Tumor growth inhibition measured at end of 28 day cycle 
(cycle = SY-5609 qd, 21d on, 7d off)
• POLR2A fold-change measured at steady state (day 15) • POLR2A fold-change similar between PBMCs and 
tumor biopsies
POLR2A PD vs Tumor Growth Inhibition
SY-5609 CRC PDX 
POLR2A PD vs CDK7 Occupancy
SY-1365-101 PBMCs











































































Administration of an Intermittent Dosing 
Regimen Maintained Tumor Regressions 
in Ovarian Cancer Xenografts
• SY-5609 dosed po daily (QD) or with a 7-day-on/7-day-off 
(7/7) schedule per 28-day cycle; data through day 42 
shown, study ongoing; dashed horizontal line represents 
average starting tumor volume
• Both dosing regimens were well-tolerated: mean body 
weight changes on day 42 were +8% for 6 mg/kg 7/7 and 
+4% for 3 mg/kg QD
Tumor volume vs time
OVCAR3 xenografts 




















 0 mg/kg QD
 3 mg/kg QD
 6 mg/kg 7/7
Single Agent Continuous Daily Dosing (QD – 28 days each 28-day cycle)
Breast Cancer Combination with Fulvestrant (SY-5609 dosed 3 weeks on; 1 week off)
3 mg Cohort Expansion 
in Breast Cancer
3 mg Cohort Expansion
in Lung Cancer
Cohort 1
1 mg Cont. Daily
Cohort 4
4 mg; Cont. Daily
Cohort 3 
5 mg Cont. Daily
Cohort 5
4 mg; 7d on/ 7 off
Cohort 6
4 mg; 5d on/ 2 off
Escalation to next dose level
Escalation to next dose level
Cohort 2 
3 mg Cont. Daily
3 mg Cohort
3 weeks on/1 week off
Escalation to next dose level
6 of 17 patients were response evaluable
Single Agent Cohort:
• 2 patients at 3 mg daily achieved stable disease as the best response 
   –  Includes 1 patient with HR+ breast cancer and 1 patient with colorectal cancer
• 1 patient at 5 mg daily achieved stable disease as the best response
   –  Patient with esophageal cancer (CCNE1 amplification and CDKN2A deletion)
• 2 patients, 1 each at 1 mg and 3 mg daily demonstrated progressive disease 
   –  Both patients with ovarian cancer (1 with CCNE1 amplification at 3 mg dose)
Combination Cohort:
• 1 patient demonstrated progressive disease
11 of 17 treated patients were not response evaluable at 
the time of the data-cut
• 2 patients had discontinued treatment prior to the first response 
assessment timepoint 
   –  1 patient at 3 mg and 1 patient at 5 mg
• 9 patients had not reached the first response assessment timepoint 
at the time of the data-cut
   –  3 patients each at 3 mg, 5 mg and in the combination regimen 
Note: 3 mg group contains data from single agent and combination patients
* Patients with evaluable PK






































































































• PK and PD data were available at the 3 mg continuous daily dose level to support an analysis of POLR2A PD at steady state on Day 15
• POLR2A PD responses at Day 15 were enhanced relative to Day 1, consistent with increased SY-5609 exposure at steady state
